Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65.8M
-
Number of holders
-
109
-
Total 13F shares, excl. options
-
34.5M
-
Shares change
-
-2.29M
-
Total reported value, excl. options
-
$709M
-
Value change
-
-$40.3M
-
Put/Call ratio
-
0.66
-
Number of buys
-
55
-
Number of sells
-
-65
-
Price
-
$20.60
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q1 2021
150 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $.001 as of Q1 2021.
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.5M shares
of 65.8M outstanding shares and own 52.41% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (3.91M shares), Redmile Group, LLC (3.39M shares), EVENTIDE ASSET MANAGEMENT, LLC (2.06M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.9M shares), WELLINGTON MANAGEMENT GROUP LLP (1.89M shares), STATE STREET CORP (1.88M shares), VANGUARD GROUP INC (1.8M shares), Vivo Capital, LLC (1.29M shares), VR Adviser, LLC (1.24M shares), and ACUTA CAPITAL PARTNERS, LLC (1.02M shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.